In a clinical setting, IFN-α gene therapy could exert tumour suppressive effects based both on direct cytotoxicity and indirect immunological antitumour activities, the combination of which is expected to be highly efficacious against locally advanced pancreatic cancer. Here, IFNA2 is linked to familial pancreatic carcinoma.